ClinicalTrials.gg
CompletedNCT02042014Updated Jun 18, 2019Results posted

Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

A Phase 3 interventional study of QTI571 in Severe Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
10th of 12
8 · median 27
Started
2014
the only one that year
Phase 3
5 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 3, and was the 7th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.

Read the detailed description

This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study (A2301E1) and were judged by the investigator to benefit from continued QTI571 treatment.

03

Conditions studied

  • Severe Pulmonary Arterial Hypertension

Keywords

  • Pulmonary arterial hypertension, QTI571, open label study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan.
  • Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Patient has been permanently discontinued from QTI571 study treatment in the parent study.
  • Concomitant use of oral vitamin K antagonist medication.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    QTI571

    Participants will receive QTI571 during 3 years.

    Drug: QTI571

Interventions

  • DrugQTI571

    QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.

    Time frame: Approximately 2.9 years

07

Results

Posted Jun 18, 2019
Limitations and caveats
No efficacy data was captured in this study, and no analysis of efficacy was planned. No formal analyses of Adverse Events were undertaken.

Participant flow

8 participants entered this study after completing the CQTI571A2301E1 study. All 8 participants discontinued study prematurely.

Participant flow — Overall Study
MilestoneQTI571
Started8
Completed0
Not completed8
Withdrew: Adverse event1
Withdrew: Physician decision7

Outcome measures

PrimarySerious Adverse Events

All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects.

Time frame:
Approximately 2.9 years
Reported as:
Number · participants
Serious Adverse Events
participantsQTI571
Cardiac disorders (5 events)5
Infections and infestations (5 events)3
Resp, thoracic,mediastinal & disorder (2 events)1
Product issues (3 events)1
Death (none)0
Skin & subcutaneous tissue disorder(1 event)1

Adverse events

Collected over Adverse events were collected up to approximately 2.9 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QTI571—5/8 (62.5%)0/8 (0%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventQTI571
Right ventricular failureCardiac disorders3/8
Acute myocardial infarctionCardiac disorders1/8
Supraventricular tachycardiaCardiac disorders1/8
CellulitisInfections and infestations1/8
GangreneInfections and infestations1/8
Respiratory tract infectionInfections and infestations1/8
Urinary tract infectionInfections and infestations1/8
Device connection issueProduct Issues1/8
Device occlusionProduct Issues1/8
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders1/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)QTI571
<=18 years0
Between 18 and 65 years7
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)QTI571
Female8
Male0
08

Study locations

3 sites
  • Novartis Investigative Site
    Sendai-city, Miyagi 980-8574, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8655, Japan
  • Novartis Investigative Site
    Mitaka-city, Tokyo 181-8611, Japan
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Oct 2016, 32 months.

Results were first posted in Jun 2019, 2 years 8 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 32 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2014
First posted
Jan 22, 2014
StartActual
Jan 22, 2014
Primary completionActual
Oct 17, 2016
CompletionActual
Oct 17, 2016
Results first posted
Jun 18, 2019
Last update
Jun 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02042014
Responsible party
Sponsor
First posted
Jan 22, 2014
Start date
Jan 22, 2014
Primary completion
Oct 17, 2016
Completion
Oct 17, 2016
Results posted
Jun 18, 2019
Last update
Jun 18, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion